Andrew Berchuck, MD

Duke University

BerchuckDr. Berchuck is Director of the Duke University Division of Gynecologic Oncology and also serves as Director of the Gynecologic Cancer Program in the new Duke Cancer Institute. He attended medical school and received obstetrics and gynecology training at Case Western Reserve University, and completed research and clinical training in gynecologic oncology at the University of Texas Southwestern and Memorial Sloan-Kettering Cancer Center. Dr Berchuck has been at Duke for 24 years and is the F. Bayard Carter Professor of Obstetrics and Gynecology.

Dr. Berchuck has been actively involved in caring for women with gynecologic cancers on a daily basis while also leading a nationally recognized program in translational research. He is a leader of the North Carolina Ovarian Cancer Study, which is a population-based, case-control, molecular epidemiological study. He also serves as the head of the steering committee of the Ovarian Cancer Association Consortium, an international group of 40 studies that are working together to validate the results of genetic association studies. Identification of ovarian cancer susceptibility polymorphisms could facilitate risk stratification and enhance screening and prevention strategies by allowing these to be focused on higher-risk populations. He serves as a participant in the ovarian and endometrial cancer working groups of the Cancer Genome Atlas Project.

Dr. Berchuck has been involved in a number of national activities, and he led the scientific advisory committee of the Ovarian Cancer Research Fund (OCRF) from 2003-2010. In 2005 he was awarded the Barbara Thomason Ovarian Cancer Professorship by the American Cancer Society. He served as President of the Society of Gynecologic Oncologists in 2007.

Spotlight

Visit the Sisterhood of Survivorship page to read “Dena’s Story” — by a vulvar cancer survivor who has shared her story and wise words, and channeled her energy into her National Race to End Women’s Cancer team.

Awareness

Vaccine efficacy against vulvar infection with HPV 16/18 was comparable to the efficacy found against cervical infection 4 years after vaccination, according to researchers with the National Cancer Institute.

Research

The Foundation has published its 2014-2015 Research Grants and Awards Booklet with Applications. Please consider applying to become part of an elite group of physician-scientists committed to the well-being of women at risk for/affected by gyn malignancies.

Education

The next Ovarian Cancer Survivors Course will be Saturday, July 26, 2014 in Boston. For more information on courses, click here.